Who Holds the Patents for Keytruda?
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., holds the primary patents for Keytruda (pembrolizumab), including composition-of-matter and method-of-use patents covering its PD-1 inhibitor cancer immunotherapy.[1][2]
Key Patents and Expiry Dates
Keytruda's core U.S. patent (US 8,354,509) covers the antibody structure and expires in 2028, with pediatric exclusivity extending it to January 2029. Multiple secondary patents, such as those for manufacturing processes and specific formulations (e.g., US 9,220,777), extend protection into the mid-2030s.[2][3]
For a full list of active patents, formulations, and expiry timelines, check DrugPatentWatch.com's Keytruda page: DrugPatentWatch - Keytruda Patents.[2]
Why Are There Patent Challenges?
Companies like Samsung Bioepis, Viatris, and Accord BioPharma have filed FDA abbreviated biologics license applications (aBLAs) with Paragraph IV challenges against Merck's Keytruda patents, triggering litigation. These disputes focus on validity and infringement, potentially accelerating biosimilar entry if successful.[2][4]
When Can Biosimilars Enter the Market?
No biosimilars are approved yet. The earliest likely U.S. entry is 2028 post-patent expiry, though settlements or court wins could shift this to 2029 or later. Europe sees potential launches around 2025-2026 after EMA approvals, but U.S. exclusivity blocks imports.[2][3]
How Does This Affect Pricing and Access?
Keytruda generated $25 billion in 2023 U.S. sales for Merck. Patent protections sustain high list prices (around $11,000 per month), but biosimilars could cut costs 20-30% upon entry, improving patient access for cancers like melanoma and lung cancer.[4]
Sources
[1]: USPTO Patent Full-Text Database - US 8,354,509 (https://patents.google.com/patent/US8354509B2/en)
[2]: DrugPatentWatch - Keytruda (https://www.drugpatentwatch.com/p/tradename/KEYTRUDA)
[3]: FDA Orange Book - Keytruda Exclusivity (https://www.accessdata.fda.gov/scripts/cder/ob/patentinfo.cfm?ProductNo=001&ApplNo=125514&Appltype=B)
[4]: Merck Q4 2023 Earnings Report (https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/)